Oestrogen plus progestogen v placebo in postmenopausal women*
| Annualised percentage developing coronary heart disease (CHD) | |||
|---|---|---|---|
| Outcomes at mean 5.3 years | Oestrogen plus progestogen | Placebo | Adjusted hazard ratio (95% CI) |
| *CI defined in glossary. Hazard ratio adjusted for the presence or absence of previous coronary revascularization and sequential monitoring. | |||
| †Not significant. | |||
| All CHD | 0.39% | 0.33% | 1.24 (0.97 to 1.60)† |
| Non-fatal myocardial infarction (MI) | 0.31% | 0.25% | 1.28 (0.96 to 1.70)† |
| Nonfatal MI (excluding silent MI) | 0.31% | 0.24% | 1.30 (0.97 to 1.74)† |
| Death caused by CHD | 0.08% | 0.08% | 1.10 (0.65 to 1.89)† |
